Omnicell, Inc. (NASDAQ:OMCL) Given Average Rating of “Buy” by Brokerages

Shares of Omnicell, Inc. (NASDAQ:OMCL) have received an average recommendation of “Buy” from the nine ratings firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $59.8571.

Several brokerages recently weighed in on OMCL. UBS Group set a $60.00 target price on shares of Omnicell and gave the stock a “buy” rating in a report on Friday, March 13th. Weiss Ratings raised Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a report on Thursday, May 7th. Zacks Research upgraded Omnicell from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 1st. Benchmark reaffirmed a “buy” rating on shares of Omnicell in a research note on Friday, March 13th. Finally, Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th.

Insider Buying and Selling

In other news, EVP Corey J. Manley sold 5,025 shares of Omnicell stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $217,180.50. Following the sale, the executive vice president owned 112,783 shares in the company, valued at $4,874,481.26. This trade represents a 4.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the business’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $133,549.80. Following the completion of the transaction, the executive vice president directly owned 154,785 shares in the company, valued at $6,689,807.70. This trade represents a 1.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is currently owned by insiders.

Institutional Trading of Omnicell

Institutional investors and hedge funds have recently bought and sold shares of the stock. Raymond James Financial Inc. purchased a new stake in Omnicell in the 2nd quarter worth $26,000. Versant Capital Management Inc grew its position in shares of Omnicell by 38.7% during the second quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock valued at $44,000 after purchasing an additional 294 shares in the last quarter. Clearstead Advisors LLC increased its holdings in shares of Omnicell by 12,180.0% in the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock worth $56,000 after purchasing an additional 1,218 shares during the last quarter. Kemnay Advisory Services Inc. bought a new stake in shares of Omnicell in the fourth quarter worth about $58,000. Finally, Parkside Financial Bank & Trust increased its holdings in shares of Omnicell by 1,708.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock worth $61,000 after purchasing an additional 1,264 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors.

Omnicell Price Performance

Shares of NASDAQ:OMCL opened at $45.12 on Thursday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.50 and a quick ratio of 1.29. Omnicell has a 1-year low of $26.84 and a 1-year high of $55.00. The company has a market capitalization of $2.05 billion, a P/E ratio of 102.55, a P/E/G ratio of 1.15 and a beta of 0.96. The firm’s 50 day simple moving average is $42.20 and its two-hundred day simple moving average is $41.50.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. The business had revenue of $309.88 million during the quarter, compared to analyst estimates of $304.02 million. Omnicell had a net margin of 1.67% and a return on equity of 4.00%. The company’s revenue was up 14.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.26 earnings per share. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. Research analysts expect that Omnicell will post 1.31 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.